Evidence map›Paper›PMID 41782993›Full record

ReviewMaterials today. Bio2026

Revolutionizing protein degradation: Harnessing nanoparticles for PROTAC delivery.

Yonghang Fan, Jianfen Su, Jun Yang, Xiaoling Guan, Yingjie Gong, Daliang Yang, Aiping Qin, Lingmin Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yonghang FanThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.
Jianfen SuThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.
Jun YangThe Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, 510260, PR China.
Xiaoling GuanThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.
Yingjie GongThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.
Daliang YangShenzhen Bao'an District Songgang People's Hospital, Shenzhen, 518000, PR China.
Aiping QinThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.
Lingmin ZhangThe Affiliated Panyu Central Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangdong Basic Research Center of Excellence for Respiratory Medicine, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteolysis-targeting chimera (PROTAC) represents a paradigm shift in drug discovery, offering a promising therapeutic strategy for cancers, neurodegenerative diseases, and hematological malignancies. Unlike traditional small-molecule inhibitors that require occupancy of an active site, PROTAC operates via an event-driven mechanism, hijacking the ubiquitin-proteasome system to degrade target proteins. This approach can potentially convert "undruggable" targets into tractable ones, dramatically expanding the druggable proteome. However, the clinical translation of PROTAC faces a significant bottleneck due to inherent physicochemical and pharmacokinetic challenges, including poor solubility, limited membrane permeability, and off-target effects. Nanomedicine delivery systems have emerged as a powerful platform to overcome these hurdles. By encapsulating or conjugating PROTAC, nanocarriers can enhance bioavailability, improve cellular delivery, and increase target specificity, thereby unlocking their full therapeutic potential. This review systematically examines recent advances in nanoparticle-based PROTAC delivery. We illustrate how nanocarrier design-spanning organic, inorganic, biomimetic, and prodrug platforms-can optimize PROTAC properties and enhance therapeutic outcomes. Furthermore, we analyze current limitations and outline future directions to guide the development of next-generation delivery strategies, with the ultimate goal of accelerating the clinical translation of these transformative agents.

Indexed as

Drug deliveryNanoparticle delivery systemPrecision therapiesPROTACTargeted protein degradation

Identifiers

PMID41782993
PMCPMC12955651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.